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In 1906 Dale
1
showed that an extract from the posterior
pituitary gland stimulated uterine activity. Three years later
Blair Bell
2
reported its efficacy in the treatment of
postpartum haemorrhage.  In 1927 Bourne and Burn
concluded that oxytocin may be valuable in cases where
labour is prolonged secondary to ‘sluggish pains’.
3
Du
Vigneaud was the first person to synthesise this
polypeptide hormone and in 1955 received the Nobel Prize
for his work.
4
Oxytocin is a nonapeptide hormone, produced in the
hypothalamus, stored in the posterior pituitary gland, and
secreted in a pulsatile way.  Oxytocin receptors are found in
the myoepithelial cells of the breast, the myometrium and
the decidua.
5
Myometrial oxytocin sensitivity increases
through pregnancy.
6
The concentration of myometrial
receptors increases towards term and may be particularly
high in patients with preterm labour.
7
Myometrial gap
junctions also increase as gestation advances, possibly
enhancing the sensitivity of the myometrium to uterotonic
agents and helping to maintain effective contractions.
8
In pregnancy, oxytocinase (circulating aminopeptidase) is
produced by the placenta and significantly increases the
metabolic clearance rate of oxytocin.
9
The exact
pharmacological half-life of oxytocin is controversial
10
but
available data suggest that a stable uterine response is
obtained 40 - 60 minutes after initiating a constant-dose
infusion.
11,12
Therefore the physiological half-life may be
close to 10 minutes, since approximately four ‘half-lives’ are
required to obtain constant plasma levels.
5
Oxytocin is one of the most commonly used drugs in
labour, and there are many different dosage regimens.
However, if oxytocin is used incorrectly it can lead to major
complications such as fetal hypoxia, hyperstimulation of
the uterus and even uterine rupture.  The aim of this study
was to examine the use of oxytocin by practising
obstetricians in South Africa.
Methods
A specially designed questionnaire was drawn up and
reviewed by a panel of practising obstetricians.  A total of
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350 questionnaires (in both
English and Afrikaans) were
distributed to specialists
according to an address list
obtained from the South African
Society of Obstetricians and
Gynaecologists. Each
questionnaire was divided into
two sections: the first dealt with
induction of labour and the
second with augmentation of
labour.  Every questionnaire was
accompanied by a covering letter
explaining the aim of the study, as
well as a stamped self-addressed
envelope. All the questionnaires
were returned anonymously. The
forms were distributed between
August and December 2002.
Results
Of the 350 questionnaires
distributed, 185 questionnaires
were returned.  Eleven doctors
were either abroad or retired, and
therefore not practising in South
Africa. One hundred and seventy-
four questionnaires were
processed, giving a response rate
of 51.3% (Table I).
Induction of labour
In the section dealing with
induction of labour, 90.8% of
obstetricians would not use
oxytocin in patients who had an
unfavourable cervix (Bishop score
of less than 6) and 60.5% said that
they would not consider the use of
oxytocin if the patient had intact
membranes.
If a primigravida’s membranes
had ruptured, 18.9% of clinicians
said that they would administer
oxytocin immediately, 36.7% said
they would wait 1 hour, and 21.3%
said they would wait 6 hours
before starting with an oxytocin
infusion.
In the case of multigravid women,
11.8% of obstetricians said they
would start oxytocin immediately,
30.8% said they would wait 1
hour, and the majority of clinicians
(33.1%) said they would wait 6
hours.
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Question Answer (N) Percentage
Induction of labour
1. Oxytocin use with unfavourable cervix Yes   16 9.2 
No    157 90.8 
2. Oxytocin use with intact membranes Yes   68 39.5 
No    104 60.5 
3. Time after ROM
Primigravida
Immediately 32 18.9 
1  hour 62 36.7 
6  hours 36 21.3 
12 hours 11 6.5 
24 hours 10 5.9 
Other 17 10.1 
Not at all 1 0.6 
Multigravida 
Immediately 20 11.8 
1  hour 52 30.8 
6  hours 36 33.1 
12 hours 10 5.9 
24 hours 9 5.3 
Other 22 13 
4. Use with one previous caesarean section Yes   51 29.7 
No    121 70.3 
5. Use with viable twin pregnancy Yes   62 36.3 
No    109 63.7 
6 . Use with multigravida Yes   159 94.6 
No    9 5.4 
7 . Use with grand multipara Yes   47 28.1 
No    120 71.9 
8. Same regimen as with primigravidas 46 30.3 
Lower dose than with primigravidas 106 69.7 
9. Fetal heart monitoring 
Fetal stethoscope + intermittent CTG 4 2.4 
Intermittent CTG 38 22.8 
Intermittent + continuous CTG 7 4.2 
Intermittent CTG + doptone 4 2.4 
Continuous CTG 114 68.3 
10. Administering method
Electronic pump 150 90.4 
Non-electronic device 14 8.4 
None of the above 2 1.2 
Augmentation of labour
1. Oxytocin with intact membranes Yes   71 41.3 
No    101 58.7 
Table I.        Oxytocin use in pregnancy — results of questionnaire
pg 28-38 q5  6/14/05  10:41 AM  Page 29
With regard to previous caesarean sections, 70.3% of
obstetricians said they would not use oxytocin in patients
with a previous lower-segment caesarean section.
A total of 63.7% of doctors said they would not consider
oxytocin use in a patient with a multifetal pregnancy.
Most respondents said they would use oxytocin for
induction of labour in multigravid patients; only 5.4% said
they would not use it.  However 71.9% of doctors said they
would not use oxytocin to induce labour in grand-
multiparous patients. Most doctors (69.7%) said they would
use a lower-dose regimen with multigravid than with
primigravid patients.
With regard to monitoring the patient, 68.3% said they
would use continuous cardiotographic (CTG) monitoring
while administering oxytocin, 22.8% said they would use
intermittent CTG monitoring, while the remainder said
they would use a combination of fetal stethoscope and CTG
monitoring.
Augmentation of labour
The second section of the
questionnaire dealt with augmentation
of labour.  It showed that 58.7% of
obstetricians would not use oxytocin
in a patient with intact membranes
and 65.3% would not augment
patients who had had a previous
(lower-segment) caesarean section.
The majority of doctors (60.7%) said
they would not use oxytocin
augmentation in a patient with a
multifetal pregnancy.
The majority of respondents (91.9%)
said they would use oxytocin to
augment labour in multigravid women;
however if the patient was a grand
multipara, 72.3% said they would not
use oxytocin. In  multiparous patients,
66.4% of doctors said they would use a
lower dose than in primigravidas.
Most clinicians (74.7%) agreed that the
desired number of contractions is 3 in
10 minutes, whereas 21.1% of doctors
preferred 4 strong contractions in 10
minutes.  Only 3% of doctors accepted
5 strong contractions in 10 minutes.
Most obstetricians (71.9%) said they
would wait 30 minutes before
increasing the oxytocin dosage if
contractions were suboptimal, while
14.9% said they would increase the
dosage every 15 minutes.
If a prostaglandin analogue was used
for induction of labour, 25.6% of
obstetricians said they would wait 4
hours before starting oxytocin infusion,  50% said they
would wait at least 6 hours, and 7.7% of respondents said
they would wait longer than 6 hours.
Of the 174 respondents, 73.1% were in private practice,
13.2% in academic institutions, 11.4% worked in both
private practice and academic institutions, and 2.4%
worked in non-academic government hospitals.  
Discussion
A total of 350 questionnaires were posted and 185 returned,
of which 174 (51.3%) could be processed. According to
Babbie et al.
13
a response rate of 50% or more is adequate
for robust analysis and interpretation.
Labour is induced when delivery will benefit the health of
the fetus and/or the mother.
14
Obstetricians should be
familiar with the indications for induction of labour, and the
chance of successful induction depends a great deal on the
condition of the cervix. According to Hofmeyr,
15
the cervix
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Table I, continued  
2. Use with one previous caesarean section Yes   60 34.6 
No    113 65.3 
3. Use with viable twin pregnancies Yes   68 39.3 
No    105 60.7 
4. Use with multigravida Yes   159 91.9 
No    14 8.1 
5. Use with grand multipara Yes   48 27.7 
No   125 72.3 
6. Same regimen as with primigravida 51 33.6 
Lower regimen than with primigravida 101 66.4 
7. Contractions/10 min 2 :     2 1.2 
3 :    124 74.7 
4 :    35 21.1 
5 :     5 3
8. Time after prostaglandin (hrs)
1  4 2.6 
2  9 5.8 
3  8 5.1 
4  40 25.6 
5  5 3.2 
6  78 50 
More 12 7.7  
9. Dosage increase after
15 min 24 14.6 
30 min 119 71.9 
45 min 13 7.9 
60 min 8 4.9 
ROM = rupture of membranes; CTG =  cardiotocogram.
pg 28-38 q5  6/14/05  10:41 AM  Page 30
S
A
JO
G
32
Ju
n
e 
20
05
, 
V
ol
. 
11
, 
N
o.
 2
Oxytocin No oxytocin 
Series Year Trials of Vaginal delivery Trials of Vaginal
labour (%) of labour delivery (%)
Meehan22 1988 261 235  (90) 298 240 (81)
Flamm et al.23 1987 282 194 (69) 1 291 1 005 (78)
Silver and Gibbs24 1987 64 40 (63) N/A N/A
Paul et al.25 1985 257 177 (69) 594 537 (90)
Chelmow and Laros26 1992 62 46 (74) 442 245 (55)
Phelan et al.27 1987 793 557 (70) N/A N/A
Table II.    Successful oxytocin administration during trials of labour after previous caesarean sections 
undergoes physiological change during pregnancy.  In the
first trimester the cervix consists mostly of tightly aligned
collagen (50%), 20% smooth muscle and the remainder is
ground substance, including elastin and glycosamino-
glycans.  As pregnancy advances, hyaluronidase increases
from 6% to 33%, whereas other glycosaminoglycans
(dermatin and chondroitin), which bind collagen more
tightly, decrease.  Collagenase, the vascularity of the cervix
and its water content increase during pregnancy. In 1964
Bishop
16
designed a pelvic scoring system (which has since
been modified) to assess the condition of the cervix.  The
chance of successful induction with oxytocin depends a
great deal on the Bishop score; a score of ≥ 9 was
associated with a > 50% delivery rate within 5 days without
any intervention.
Local application of prostaglandin E2 gel (dinoprostone) is
widely used for cervical ripening and induction of labour.17
Oxytocin may also be used for this purpose, but controlled
studies have indicated that oxytocin is not very effective
when the cervix is unfavourable when compared with local
prostaglandins.
18
The present study showed that most
obstetricians (90.8%) would not use oxytocin infusion for
induction if the cervix was unfavourable. When induction is
commenced with prostaglandins, the latest evidence-based
guidelines
19
specify that the interval between prostaglandin
doses should be 6 hours. However, the shortest safe time
interval between prostaglandin administration and the
initiation of oxytocin use has not yet been established.
According to the manufacturer’s guidelines, oxytocin
should be delayed for 6 - 12 hours following prostaglandin
administration.
17
Over 50% of obstetricians in South Africa
follow the abovementioned guidelines.
Another common method of induction of labour is artificial
rupture of the membranes.  With the HIV pandemic it is
vital to know the patient's HIV status, since amniotomy
can lead to vertical transmission.  There is still uncertainty
in the literature regarding the safe time interval between
amniotomy and commencement of oxytocin infusion.  The
general consensus is that prostaglandins are released
during low amniotomy and this stimulates labour.  Oxytocin
should be started 1 hour after amniotomy to allow the
locally released prostaglandins to facilitate contractions and
to avoid possible uterine hyperstimulation.  The majority of
clinicians surveyed nationally employ this regimen,
although 21.3% wait 6 hours after amniotomy before
starting oxytocin.
Another interesting fact that came to light in this study
was that most obstetricians in South Africa would not use
oxytocin for either induction or augmentation of labour in a
patient with a previous (lower-segment) caesarean section.
Could this possibly be explained by Edwin Cragin’s well-
known statement in 1916:  ‘once a caesarean, always a
caesarean’?
20
One of the biggest fears among obstetricians
who allow a trial of scar is the risk of uterine rupture.
Arulkumaran et al.
21
reported the risk of scar rupture to be
small if progress of labour in response to oxytocin is
satisfactory.  They suggested that a satisfactory rate of
cervical dilatation in the presence of optimal uterine
activity is predictive of a favourable outcome when
oxytocin is used for dysfunctional labour after a previous
caesarean section.
21
Several studies
22-27
consider the risk of scar rupture in
patients with a previous caesarean section who received
oxytocin for either induction or augmentation of labour
(Table II). Flamm et al.
23
had no uterine rupture in their
study and no maternal or perinatal mortality. Paul et al.
25
investigated low-dose oxytocin use in patients with a
scarred uterus and found a dehiscence rate of 3%. There
was no ‘true’ rupture secondary to oxytocin use. In 1991
Rosen et al.
28 
published a meta-analysis describing the
morbidity of vaginal birth after caesarean section.  It
included 31 studies with more than 11 000 patients, and
the (intended) route of delivery was observed to have made
no difference to the rate of uterine dehiscence or rupture.
The use of oxytocin, a recurrent indication for the previous
caesarean section and the presence of an unknown type of
uterine scar were also not associated with dehiscence or
rupture.
28
This study showed that obstetricians are reluctant to use
oxytocin for either induction or augmentation of labour in
patients with multifetal pregnancies.  The literature on the
use of oxytocin in twin pregnancies is very limited.  In 1967
Niemand et al.
29
looked at the use of oxytocin augmentation
in 127 women with twin pregnancies, of whom two-thirds
were multigravid.  Oxytocin was commenced during the
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first stage of labour and continued through to the third
stage.  They suggested that overdistension of the uterus is
apparently not a contraindication to intravenous oxytocin
and that there are no significant untoward effects from its
use.  Eighty-five per cent of women who displayed the
dysfunctional type of labour commonly found in twins had
vaginal deliveries. Fausett et al.
30
published a retrospective
study in 1997 comparing twin with singleton pregnancies
in terms of maximum dose of oxytocin used and successful
vaginal deliveries.  Oxytocin stimulation in twins resulted
in fewer interruptions of the infusion for fetal heart rate
abnormalities (5% for twins versus 26% for singleton
pregnancies) and less hyperstimulation (6% v. 18%).
Recently Harle et al.
31
conducted a case-controlled study
comparing oxytocin induction with expectant management
in uncomplicated twin pregnancies. They concluded that
induction of labour may be proposed to patients with
uncomplicated twin pregnancies after 36 weeks’ gestation
without increasing maternal or fetal morbidity.
Despite the literature, doctors are still hesitant to use
oxytocin for either induction or augmentation of labour in
patients with multifetal pregnancies, as is evident in this
study.  According to the Royal College of Obstetricians and
Gynaecologists (RCOG)
32
no conclusion can be drawn from
the available evidence regarding the merits of an active
policy for induction of labour in twin pregnancies.  If there
is careful monitoring of both the fetus and the mother and if
the presenting twin is cephalic, oxytocin may be used with
caution in twin pregnancies.
Almost 70% of South African obstetricians were reluctant
to use oxytocin in a grand-multiparous patient, whether for
induction or augmentation of labour.  The data on oxytocin
use in grand-multiparous patients are very limited.  Ben-
Aroya et al.
33
published a retrospective study in 2001. Their
objective was to determine whether the use of oxytocin for
the augmentation of labour in grand-multiparous women
would increase the risk of peripartum complications.
During the period from 1989 to 1997, 424 grand-multiparous
women received intravenous oxytocin for augmentation of
labour.  All the women had fetal heart rate and uterine
contraction monitoring.  There was no significant
difference between the oxytocin group and the control
group regarding the rates of placental abruption, fetal
distress, caesarean section, retained placenta and Apgar
scores of less than seven at 5 minutes.  They did, however,
find a significantly higher vacuum delivery rate in the
oxytocin group compared with the controls (3.5% v. 1.4%
respectively, p = 0.001). 
One should exercise caution in augmenting multiparous
patients, especially grand multiparas, where the cause of
poor progress may be unrecognised disproportion.
Augmentation with oxytocin might lead to uterine rupture
and fetal death. Any excessive stimulation of the uterus
should therefore be very carefully avoided, or diagnosed
early when oxytocin is used in the multiparous or grand-
multiparous patient.
Regarding the administration of oxytocin, 74.7% of South
African obstetricians are satisfied with 3 strong
contractions in 10 minutes, whereas 21.1% said they would
increase oxytocin infusion until there are 4 strong
contractions per 10 minutes.  Some institutions use the
cut-off of 5 contractions per 10 minutes with at least 1
minute of uterine diastole,
34 
but the RCOG recommends a
maximum of 3 strong contractions every 10 minutes,
32
and
this study confirmed this policy.
Several articles have been published regarding the
incremental interval (ranging from 15 minutes to 60
minutes) of oxytocin increase.  If one bears in mind that a
stable uterine response is only obtained 40 - 60 minutes
after initiating a constant oxytocin dose infusion, then in
order to prevent uterine hyperstimulation, oxytocin should
only be increased every 30 minutes.  Most reports
32
indicate
that the use of longer intervals between increases reduces
uterine hyperstimulation, decreases the maximum used
and total dose of oxytocin and decreases the rate of
caesarean section. The American College of Obstetricians
and Gynecologists
35
also recommends 30-minute
incremental intervals. Orhue et al.
36
stated that 30-minute
incremental increases in the infusion rate of oxytocin were
superior to a 15-minute protocol in reducing the incidence
of hyperstimulation and precipitous labour in nulliparous
women.
The use of oxytocin has been associated with possible
side- effects for both the mother and fetus.  An important
adverse effect of administering oxytocin is its antidiuretic
action.
37
This effect decreases urine flow and places
women receiving oxytocin at increased risk of dilutional
hyponatraemia (water intoxication).  Therefore the total
fluid intake during oxytocin administration should be
monitored carefully.
38
The development of dilutional
hyponatraemia is enhanced when oxytocin is administered
in an electrolyte-free dextrose solution or at a rate
exceeding 20 mU/min.
39
The preferred solutions are
therefore either 0.9% sodium chloride or lactated Ringer’s
solution.
Oxytocin appears to have a high therapeutic index because
broad ranges of infusion rates and concentrations seem to
be both safe and effective.
34
O’Driscoll et al.
40
introduced
active management of labour in nulliparous women to
shorten labour at a time when the caesarean section rate
was stable at 6%.  Their regimen included early amniotomy
and prompt intervention with high-dose oxytocin in the
event of inefficient uterine contractions. However the
efficacy and safety of this protocol was not universally
accepted.  Locally, Pattinson et al.
41
compared labour
outcomes in nulliparous women using either aggressive or
expectant management protocols, and concluded that
aggressive labour management reduces the caesarean
section rate in nulliparous women, but it requires more
intensive nursing. Satin et al.42 studied a high-dose
oxytocin regimen (6 mU/minute dosage increments) versus
a low-dose regimen (1 mU/minute dosage increment) for
labour stimulation.  They found that the high-dose regimen
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International recommendation South African use
Induction of labour
1.  Primigravida : time after ROM 1 hour* Immediately: 18.9%
After 1 hour:  36.7%
After 6 hours: 21.3%
After 12 hours: 6.5%
2.   Multigravida: time after ROM 1 hour* Immediately: 11.8%
After 1 hour: 30.8%
After 6 hours: 33.1%
After 12 hours: 5.9%
3.   Use with 1 previous c/s Not contraindicated20,27 29.7% use oxytocin
4.   Use with viable twins Few data 36.3% use oxytocin
Probably safe30
Augmentation of labour
1.   Use with 1 previous CS Not contraindicated20,27 34.6% use oxytocin
2.   Use with viable twins Few data 39.3% use oxytocin
Probably safe30
3.   Use with multipara No data 91.9% use oxytocin
4.   Use with grand multipara No data 27.7% use oxytocin
Probably dangerous
5.   Desired number of contractions 3 in 10 minutes33 2: 1.2%
3: 74.7%
4: 21.2%
5: 3%
6.   Fetal heart rate monitoring Continuous CTG 68.3%
7.   Time after prostaglandin use 6 hours16 1 hour: 2.6%
2 hours: 5.8%
4 hours: 25.6%
6 hours: 50%
8.   Increment intervals 30 min34 15 min: 14.6%
30 min: 71.9%
45 min: 7.9%
60 min: 4.9%
*Acceptable practice.
CS = caesarean section; CTG = cardiotocogram.
Table III.    Oxytocin — international recommendation v. South African obstetrician use
was associated with a significantly increased caesarean
section rate for fetal distress (6% v. 3%, p = 0.05), but a
lower incidence of instrumental deliveries, fewer caesarean
sections for dystocia and fewer failed inductions. 
The present study required obstetricians to state the
regimens used in their units, but unfortunately this specific
question was answered poorly and no conclusion could be
drawn.  It is clear that many different regimens are used by
clinicians.  The RCOG guidelines
33
recommend that
oxytocin infusions should be given in the smallest possible
volume, using an accurate infusion pump and should be
commenced at a rate of  1 mU/min, increased at intervals of
not less than 30 minutes (until 3 strong contractions every
10 minutes) up to a maximum rate of 12 mU/min.
According to the guidelines the total dose of oxytocin used
should not exceed 5 units. 
To the best of our knowledge this study is the first of its
kind to be conducted in South Africa. It is reassuring to
note that most of the obstetricians in South Africa follow
accepted practice (Table III). However, as demonstrated by
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their limited use of oxytocin in women who had previous
caesarean sections or with twin pregnancies, their
approach is too cautious. It is very reassuring that most
obstetricians use continuous fetal heart rate monitoring,
and that the others use intermittent monitoring in some
way or another. No one used auscultation exclusively in
these cases. On the other hand, it is also alarming that
some obstetricians use unsafe practices such as the use of
oxytocin immediately after the membranes have been
ruptured or within 6 hours of prostaglandins having been
used, and that they increase the dose rate every 15 minutes
or try to achieve a contraction frequency of 5 in 10 minutes.
It is essential that these potentially dangerous practices are
addressed in continuing professional development
programmes.
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